Eagle Pharmaceuticals (NASDAQ:EGRX) has resubmitted its U.S. marketing application for Ryanodex (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke as well as body cooling.
The company received a CRL in July 2017 citing the need for an additional clinical trial.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.